How molecular therapeutics have changed the role of radiology in lung cancer care

Gerhad Mostbeck, MD of the Otto Wagner Hospital, Vienna, Austria talks about how the aims of radiology in patients with lung cancer have completely changed over the last 20 years. This change is the result of new therapeutic options and a need for accurate radiologic staging as well as the use of multimodality imaging, especially FDG-PET, which gives not only morphologic but also functional information.
However, the remaining constant is the question of how to diagnose tissue, but not only for cytological diagnosis but also biomarker diagnosis which requires more information from histologic material and from a relatively large amount of cancerous tissue.
Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.

Share this video